ALK-Abelló (ALK-B.CO) Stock Analysis & AI Equity Report

Biotechnology DKK Explore free reports

ALK-Abelló (ALK-B.CO) overview

ALK-Abelló (ALK-B.CO) stock analysis and AI equity research. For the latest completed financial year, 2025, ALK-Abelló reported revenue of DKK 6,312m and operating profit of DKK 1,663m; the year-end share price was 228.60 DKK and market capitalisation was DKK 50,641m. ALK-Abelló is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get ALK-Abelló's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueDKK 6,445mFY 2025
Share price228.60 DKKFY 2025 year end
RevenueDKK 6,312mFY 2025
Operating profitDKK 1,663mFY 2025
Net earningsDKK 1,197mFY 2025
Market capitalisationDKK 50,641mFY 2025 year end

Figures updated on 2026-07-27. Data will be refreshed during report generation.

About ALK-Abelló

ALK-Abelló A/S is a Denmark-based specialty pharmaceutical company focused on allergy prevention, diagnosis and treatment. It develops and markets allergy immunotherapy products, including tablet, drop and injectable treatments, along with allergen extracts and diagnostics. The company also supplies source materials used in manufacturing allergy products and operates internationally.

Generate the ALK-Abelló report

ALK-Abelló is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, typically within about 30 minutes

Sources & methodology

Financial figures are sourced from Valuatum's financial model for ALK-Abelló and represent the latest completed financial year (2025). See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on ALK-Abelló

Each is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by what other analysts said the work added over the engine's report — a score out of five from people who had to read it to give it.